Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Harmony Biosciences Holdings's average Total Assets Growth Rate was 30.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 12.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 25.00% per year.
During the past 8 years, Harmony Biosciences Holdings's highest 3-Year average Total Assets Growth Rate was 225.80%. The lowest was 12.30%. And the median was 38.80%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Harmony Biosciences Holdings's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Harmony Biosciences Holdings Total Assets Related Terms
Harmony Biosciences Holdings Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harmony Biosciences Holdings Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harmony Biosciences Holdings (HRMY) has a Total Assets of $1,373.1 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Harmony Biosciences Holdings and its competitors.
Is Harmony Biosciences Holdings' Total Assets too high?
Harmony Biosciences Holdings' current Total Assets is $1,373.1 Mil. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Total Assets compare to SION and URGN?
Harmony Biosciences Holdings' Total Assets of $1,373.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Harmony Biosciences Holdings and its competitors. Harmony Biosciences Holdings's current Total Assets is $1,373.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.81, compared to a current price of $38.74 — trading 17.2% below its estimated fair value. The current Total Assets is $1,373.1 Mil. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Total Assets is $1,373.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued.
The current stock price of $38.74 is trading 17.2% below its estimated GF Value™ of $46.81.
GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.
Key valuation signals for HRMY:
Total Assets: $1,373.1 Mil
GF Value™: $46.81 vs. price of $38.74 (17.2% below fair value)
No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score
Get the complete analysis for HRMY
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRMY has been successfully added to your 
